	US 12,139,547 B2
	Agonistic anti TNFR2 antibody molecules
Björn Frendéus, Lund (SE); Ingrid Teige, Lund (SE); Linda Mårtensson, Bjärred (SE); Petra Holmkvist, Kävlinge (SE); and Monika Semmrich, Malmö (SE)
Assigned to BIOINVENT INTERNATIONAL AB, Lund (SE)
Appl. No. 17/290,340
Filed by BIOINVENT INTERNATIONAL AB, Lund (SE)
PCT Filed Nov. 1, 2019, PCT No. PCT/EP2019/080003 § 371(c)(1), (2) Date Apr. 30, 2021, PCT Pub. No. WO2020/089473, PCT Pub. Date May 7, 2020.
Claims priority of application No. 18203996 (EP), filed on Nov. 1, 2018.
Prior Publication US 2022/0002426 A1, Jan. 6, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/283 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)]

29 Claims

1. An agonistic antibody molecule that specifically binds to TNFR2 on a target cell, wherein the antibody molecule does not block TNF-α ligand binding to TNFR2, and where said agonistic antibody comprises VH-CDR1 of SEQ ID NO: 1, VH-CDR2 of SEQ ID NO: 2, VH-CDR3 of SEQ ID NO: 3, VL-CDR1 of SEQ ID NO: 4, VL-CDR2 of SEQ ID NO: 5, and VL-CDR3 of SEQ ID NO: 6.